Prevention of insulin-dependent diabetes mellitus by 2'-deoxycoformycin in the BB Wistar rat

Biochem Pharmacol. 1993 Sep 14;46(6):1071-5. doi: 10.1016/0006-2952(93)90672-j.

Abstract

The effect of the adenosine deaminase (ADA) inhibitor 2'-deoxycoformycin (dCF) on the development of insulin-dependent diabetes mellitus (IDDM) was assessed in the BB Wistar rat. Sixty-one male rats were treated from days 30 to 120 with 0, 0.5, 1.0 or 1.5 mg dCF/kg/week. The incidence of IDDM was 78% in the controls and was significantly (P < 0.01) decreased in rats receiving 1.5 mg dCF/kg/week (32%), but not in rats receiving lower doses of the drug. However, for those rats that became diabetic the mean time to the development of IDDM was unchanged in animals receiving dCF compared with control. dCF treatment did not produce significant weight loss in the animals or gross changes in the thymus, spleen or kidneys. Although the protective effect of dCF against IDDM was likely produced by immunosuppression, the different dCF dosages had similar effects on ADA suppression in spleen or thymus and on dATP accumulation in these organs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Deaminase Inhibitors
  • Animals
  • Deoxyadenine Nucleotides / metabolism
  • Diabetes Mellitus, Type 1 / genetics
  • Diabetes Mellitus, Type 1 / metabolism
  • Diabetes Mellitus, Type 1 / prevention & control*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Male
  • Organ Size / drug effects
  • Pentostatin / pharmacology*
  • Rats
  • Rats, Inbred BB / genetics
  • Spleen / drug effects
  • Spleen / enzymology
  • Thymus Gland / drug effects
  • Thymus Gland / enzymology

Substances

  • Adenosine Deaminase Inhibitors
  • Deoxyadenine Nucleotides
  • Pentostatin
  • 2'-deoxyadenosine triphosphate